

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**VOLUNTARY ANNOUNCEMENT
INSULIN DEGLUDEC AND
INSULIN ASPART INJECTION OBTAINED MARKETING APPROVAL
FROM THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed Insulin Degludec and Insulin Aspart Injection has obtained the marketing approval from the China National Medical Products Administration (NMPA), covering two types, namely cartridges type and pre-filled pens type. Details of the approval are set out below:

I. MAIN CONTENTS OF THE DRUG

1. Drug name: Insulin Degludec and Insulin Aspart Injection
2. Dosage form: Injection
3. Strength: 3ml: 300 units
4. Approval numbers: Cartridge type (National Drug Approval No. S20260074);
Pre-filled pen type (National Drug Approval No. S20260073)

II. OTHER DRUG RELATED INFORMATION

Insulin Degludec and Insulin Aspart Injection is a dual insulin analogue, consisting of 70% basal insulin degludec and 30% rapid-acting prandial insulin aspart at a fixed ratio of 7:3. The two components remain independently stable, with no mutual interference in their activities. (1) Insulin degludec provides ultra-long-acting and stable insulin release with no pronounced peak over 24 hours, enabling stable control of fasting and

baseline blood glucose levels; insulin aspart has a rapid onset of action and effectively suppresses postprandial blood glucose peaks. A single formulation can address both fasting and postprandial blood glucose control, significantly improving daily glycaemic fluctuations and increasing the proportion of patients achieving target glycated haemoglobin levels, outperforming traditional premixed insulin. (2) It is a soluble formulation that is easy to administer and supports flexible once- or twice-daily dosing, significantly simplifying treatment procedures and reducing the number of injections. It effectively alleviates patients' medication burden and improves long-term treatment adherence. (3) It can be used in insulin-naïve patients and is also suitable for patients with type 2 diabetes who have inadequate glycaemic control, significant glycaemic fluctuations, frequent hypoglycaemia or intolerance to multiple injections under conventional insulin therapy. It can meet the individualised glucose-lowering needs of different patients.

III. INSULIN LAYOUT OF THE GROUP

With the approval for marketing of Insulin Degludec and Insulin Aspart Injection, the number of the Group's approved insulin products in the Chinese market has increased to seven, establishing a full-range insulin product matrix that spans the second to fourth generations and covers three major clinical application scenarios: basal, prandial, and pre-mixed insulins.

In terms of the R&D pipeline, HEC-151, the Group's innovative ultra-long-acting weekly insulin formulation, has entered Phase I clinical trials. Moving forward, it will form a multi-tiered product echelon comprising "daily formulations — weekly formulations — combination formulations" alongside currently marketed products, enabling the continuous iterative upgrading of the Group's insulin product pipeline.

In terms of international expansion, the Group's self-developed Insulin Glargine Injection received an approval letter from the United States Food and Drug Administration at the end of April 2026, making it the fourth insulin glargine product approved for marketing in the United States, and the Company the first PRC pharmaceutical company to commercialize an insulin glargine product in the United States market. Going forward, the Group will continue to advance the overseas registration and filing of several insulin products, such as Insulin Aspart and Insulin Degludec, continuously advance the global expansion of its insulin product portfolio, expand its international market share, enhance its international operational capabilities and brand influence, and bring PRC-developed insulin products to the global market to benefit people with diabetes worldwide.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
8 October 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.